कंपनी का अवलोकन
Emergent BioSolutions Inc. operates as a specialized life sciences enterprise dedicated to delivering preparedness and response solutions for public health threats, whether they arise from accidental incidents, deliberate acts, or natural causes, serving markets across the United States, Canada, and globally. The firm functions within the Healthcare sector, specifically under the Drug Manufacturers - Specialty & Generic industry classification, which positions it as a critical provider of essential biological products and defense mechanisms rather than consumer pharmaceuticals. The company demonstrates a distinct market presence with a total market capitalization of $437.46M and generates annual revenue of $742.90M while employing approximately 900 individuals across its operational footprint. These financial dimensions indicate that while the company is not a massive market leader in terms of sheer capitalization, it maintains a substantial revenue base that supports its specialized manufacturing capabilities and logistical network required for public health emergencies.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $742.90M, accompanied by a net income of $52.60M and an EBITDA of $208.90M, revealing a significant gap between pre-tax operational earnings and final net profit that highlights a substantial cost structure involving taxes, interest expenses, and other non-operating deductions. This disparity between the robust EBITDA figure of $208.90M and the lower net income of $52.60M suggests that the firm incurs considerable costs outside of its core manufacturing operations, which must be carefully managed to preserve profitability. The business generates a free cash flow of $205.39M, indicating a strong ability to convert revenue into cash, which provides significant financial flexibility for debt repayment, operational investments, or strategic acquisitions without relying on external financing. Margin analysis shows a gross margin of 49.4%, reflecting high pricing power or low cost of goods sold relative to sales, whereas the operating margin stands at -15.2%, signaling that operating expenses currently exceed operating income, and the profit margin is 7.1%, indicating the final profitability after all expenses. Regarding capital structure, the company holds $205.40M in cash against total debt of $583.70M, resulting in a debt-to-equity ratio of 111.69, which characterizes the balance sheet as highly leveraged rather than conservative. Despite the leverage, the current ratio of 5.01 demonstrates excellent short-term liquidity, implying the firm possesses more than five times the current assets necessary to cover its immediate liabilities. Furthermore, the return on equity is 10.5% and the return on assets is 5.3%, metrics that reveal management's effectiveness in generating returns relative to the shareholders' investment and the total asset base, respectively.
मूल्यांकन आकलन
The stock carries a trailing P/E ratio of 9.09 and a forward P/E of 2.83, a substantial difference that implies the market expects a dramatic shift in future earnings or is pricing in significant uncertainty regarding the company's ability to generate consistent profits in upcoming periods. The price-to-book ratio is recorded at 0.84, indicating that the market values the company at less than its book value, which often suggests the stock is undervalued relative to assets or that investors are concerned about the quality of those assets or future liabilities. Alternative valuation metrics such as the price-to-sales ratio of 0.59 and an EV/EBITDA of 3.90 further suggest a low valuation multiple compared to many of its peers, though these figures must be interpreted alongside the company's high debt load and recent revenue contraction. The 52-week high is $14.06 and the 52-week low is $4.02, meaning the current trading price sits significantly below the recent peak, reflecting the market's reaction to the reported -23.6% revenue growth and the widening gap between operating income and expenses. The beta value of 2.36 indicates that the stock exhibits high price volatility, moving more than twice as much as the broader market in either direction, which adds a layer of risk for investors seeking stability.
Growth & Income
Emergent BioSolutions Inc. is experiencing a revenue decline of -23.6% year-over-year, while earnings growth is listed as N/A due to the lack of comparable historical data or specific reporting in the current dataset, preventing a direct comparison of earnings velocity against revenue. In the absence of a positive earnings growth trajectory to support payouts, the company currently does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all its earnings to fund operations, reduce debt, or invest in new product lines rather than returning cash to shareholders. The overall growth and income profile is defined by a contraction in top-line revenue and a highly leveraged balance sheet, where the primary strategy appears to be survival and operational restructuring rather than aggressive expansion or income generation through dividends. This combination of negative revenue growth, high debt levels, and zero dividend payouts paints a picture of a company in a transitional phase where capital preservation takes precedence over growth initiatives or shareholder returns.